The Future is Faster Than You Think: Jay Kulsh Of GEIPE Cancer Treatment Inc On How Leaders Are Preparing for The Innovations, Disruptions, and Strategies That Will Define Tomorrow
An Interview With Cynthia Corsetti
Have multiple product lines (or offerings) in unrelated fields, so if one product loses market share due to some unforeseen innovative product, you can rely on your other offerings.
The pace of change is accelerating, with innovations and disruptions reshaping industries faster than ever. Leaders must not only anticipate these changes but also develop strategies to thrive in this evolving landscape. How are forward-thinking leaders preparing for the technologies and challenges of tomorrow? What strategies are they putting in place today to ensure success in the future? As part of this series, we are interviewing Jay Kulsh.
The founder of the non-profit company, GEIPE Cancer Treatment, Inc., Jay Kulsh is an independent scientist who has published 3 peer-reviewed articles in 1997, 2014 and 2023 about cancer causation and a novel cancer treatment. He got interested in the potential role of the enzyme Ribonucleotide Reductase (RnR) in causing cancer ever since he learned about its unique structure as a graduate student at UCLA, and later came up with a treatment that efficiently blocks this RnR enzyme — pivotal for cancer growth — with gentle electric current. Top cancer institutes of the USA and India found his cancer treatment ideas “very interesting” and “worth investigating” but all have been averse to exploring and offering this treatment, perhaps because the therapy is non-patentable and very inexpensive. Through the website of the company, www.cancer-treatment.net, Jay Kulsh makes this revolutionary (effective, non-toxic & low-cost) cancer treatment available for near-surface cancers, including all skin cancers, as a home remedy, but this cancer treatment would be universally applicable in a hospital setting.
Thank you so much for joining us in this interview series. Before we dive into our discussion, our readers would love to “get to know you” a bit better. Can you share with us the backstory about what brought you to your specific career path?
My innovation is in the field of cancer, both its cause and its effective treatment.
My involvement in the field of cancer is highly unconventional. I have never been associated with any cancer research institution, nor have a medical degree. While working for my Ph.D. in the department of Chemistry/Biochemistry at University of California, Los Angeles (UCLA) in the late 1970’s, I came to know about the critical enzyme in both DNA synthesis and cancer growth, Ribonucleotide Reductase (RnR) whose active-site was very unique, having two iron atoms which stabilize a free-radical. (A ‘free-radical’ in chemistry is an exceptional and unstable molecule which has an unpaired electron. As a rule, molecules contain paired electrons, which bond various atoms.)
I had a hunch that the unique structure of RnR would be vulnerable to carcinogenic compounds, but my ideas could not be tested at that time because mammalian RnR had not been purified enough.
Even after leaving UCLA, I remained intrigued by the idea that RnR enzyme may be the site of cancer initiation, and in 1993, based on the latest scientific findings about RnR, I wrote an article citing strong circumstantial evidence that cancer originates at this enzyme. The feedback from the scientific community was that people suffering and dying from cancer don’t care for the cause, they want the cure!
This made me change the direction of my thinking: How to disable RnR by extinguishing its free-radical? (All cancer experts agree that if you can block RnR, you can stop cancer. In fact, RnR has been the target of many chemotherapeutic drugs since 1970’s, but these drugs are only partially/temporarily effective, and toxic to healthy tissues.)
It occurred to me that passing mild electric current — a stream of electrons — through cancerous tissue would pair up the lone electron of the RnR enzyme, thereby quenching the free-radical. With free-radical gone, activity of RnR will cease. The cancer would stop growing!
In 1994 I found 10 scientific reports where cancer was treated with electricity in animal studies. They all confirmed my proposition that gentle current (at low voltage) would stop cancer growth. About half the studies did not report positive results because they used higher voltage where toxic electrochemistry takes place. On the other hand, a low voltage study published in 1985 saw 98% tumor shrinkage occurring after only 5 hours of electrotherapy.
I wrote to all ten ‘Comprehensive Cancer Centers’ of the time describing the rationale of this novel cancer therapy and compelling experimental evidence in its favor. Only three institutions responded. MD Anderson Cancer Center, Houston — the topmost cancer research center — found the ideas very interesting and deserving of further investigation. But they themselves have refused to investigate it for more than 30 years, although the money needed to study cancer electrotherapy would be minuscule.
The National Cancer Institute (NCI) sent me to the City of Hope Medical Center near Los Angeles where Dr. Yun Yen was studying the RnR enzyme. He agreed with me that pure electrotherapy would block RnR and arrest cancer. But the management vetoed our collaboration because such therapy would “not bring patients” to their hospital. By ‘patients’ they really meant ‘money’.
The top cancer institute of India, Tata Memorial of Mumbai, twice showed interest in collaborating with me, but both times, abruptly changed its mind.
It is not hard to see why a cancer institution would not like to explore and offer a non-patentable and dirt-cheap cancer treatment. No hospital wants to see their most expensive treatments to become the least expensive. This is too much disruption. They have bills to pay. Alas, cancer patients are also paying — with their loss of lives and suffering.
It is a very unfortunate coincidence that the most effective, non-toxic and universal cancer treatment is not financially viable for cancer care providers.
On my own, during the last 3 decades, I built and continuously improved an electrotherapy device and — via the website www.cancer-treatment.net of a charitable foundation — reach a few patients who have near-surface tumors. Here are photos of some patients healed by this therapy, as a home-remedy:
Progressive healing of a Florida patient — from the 2014 scientific publication of the author
Can you share the most interesting story that happened to you since you started your career?
This story involves my experience with the co-discoverer of DNA structure, famed Dr. James Watson. As head of the prestigious New York scientific institution Cold Spring Harbor Laboratory, Dr. Watson directed research in the field of molecular biology for 40 years (1968–2007), where the emphasis was on the systematic study of cancer-related genes.
In 1993 I wanted to discuss with him ideas expressed in my article ‘Role of an Enzyme in the Origin of Cancer’. Eventually, he did give me time, but in that 10-minute meeting, he was unwilling to accept that biochemistry could play a role in cancer causation. He kept describing various mutated genes. I came back disappointed.
But after 23 years, I was shocked, and also delighted, when I read this statement of his in the New York Times on May 12, 2016:
“locating the genes that cause cancer has been “remarkably unhelpful”… If he were going into cancer research today, he would study biochemistry rather than molecular biology.
It was pointless to contact him now. He was 88 years old and retired.
It did show that in the field of cancer I was ahead of Dr. James Watson by about 20 years.
Please note: Looking at cancer with the correct point of view — biochemistry rather than genetics — makes all the difference. Cancer becomes an easy disease to understand and treat. (Remember, all planetary motions were considered extremely complex till we realized that planets are moving around the sun, not earth — so, perspective is very important.)
What do you think makes your company stand out? Can you share a story?
Our company is called GEIPE Cancer Treatment, Inc. (GEIPE stands for Gentle Electrotherapy to Inhibit (block) a Pivotal Enzyme.) We offer a revolutionary therapy that stands out in the field of cancer treatments in multiple ways:
- Effective: Vast majority of patients who have tried this therapy have benefited from it. Many have been healed fully. Exceptions are those cases where cancer is in the late stages since as home remedy we cannot treat cancer that has spread internally, or if it starts “eating away” at healthy tissues. Traditional cancer treatments are rarely or temporarily effective.
- Non-toxic: Surgery, radiation and chemotherapy are traditional cancer treatments and have been called “Slash, burn and poison” by oncologists themselves. Patients often fear side-effects of these treatments as much as they fear the disease itself. On the other hand, this gentle electrotherapy treatment has no toxic side effects. At most, some patients may suffer occasional skin burns which are painless and heal within 1–2 weeks.
- Universal: At biochemical level, all cancers are alike. They all need to synthesize DNA for cells to grow. This treatment, based on understanding of the biochemical mechanism of cancer growth would be applicable, in theory, to all cancers. Since recent studies suggest that cancer is likely initiated at the site of RnR enzyme, we will be nipping cancer in the bud by this therapy.
- Low cost: Unlike other cancer treatments, it is a very affordable treatment. In fact, it is so low cost that no cancer institution wants to touch it, fearing a precipitous drop in their income.
RELATED STORY: In 1994, the book “Cross Currents: The Perils of Electropollution, the Promise of Electromedicine” by Dr. Robert O. Becker informed me about the first modern attempt at cancer electrotherapy, whose beneficial results were published in 1959 in journal Science.
I then found subsequent scientific studies, which further confirmed the effectiveness of such a cancer therapy. This strongly supported my proposed mechanism involving the free-radical of enzyme RnR. I enthusiastically called the author Dr. Becker. He listened to my ideas, agreed, but said that such a treatment cannot be patented and is very cheap so no cancer organization will touch it. “Cancer supports more people than it kills. This treatment will never see the light of the day.”
It was very disheartening to hear his pessimistic views. I did not want to believe him. But he was right, of course; I am still struggling after 30 years.
Thus, my company stands out — so much so that there is an intense passive resistance to it.
You are a successful business leader. Which three character traits do you think were most instrumental to your success? Can you please share a story or example for each?
Our success is really incremental progress, under trying circumstances.
The character traits needed for success are:
Perseverance:
Since no cancer institution would take interest in a dirt-cheap treatment, no matter how effective, I made a website in 2003 to make the public at large aware of this cancer treatment. At the urging of a few visitors, I built a simple device for the treatment and constantly made improvements to it. Got a few patients who were in late stages of cancer. Those early devices could only ameliorate pain and reduce seepage of cancer wounds. An engineer heard about this treatment and built an electronic device for his father-in-law and could fully heal his Merkel cell carcinoma. That inspired me to get an electronic device manufactured. Then I went to India in 2010 and met many oncologists. Only one was willing to collaborate and gave 2 patients who were untreatable by him. When they showed clear improvements, even he stopped cooperating. Since then we have relied solely on the website to attract a few patients.
Constant Improvement Of The Product:
The ‘product’ in our case is the treatment device and the protocol. We have constantly improved the GEIPE device since 2005. The current device is the 2nd electronic version. Equally importantly, learning from the experience of patients, we keep optimizing the procedure, always remembering that the target is an enzyme which is only active during cancer growth. Thus, when tumors stop responding, we advise patients to use a semi-invasive procedure which makes cancer ‘wake up’ and become responsive to the therapy.
Nonstop Promotion and Marketing:
In our case, due to lack of resources, we constantly contact, via emails, healthcare journalists, maverick cancer professionals and cancer charities (which are not associated with hospitals or pharmaceuticals — a rarity) to make our treatment better known. As a non-profit, we were able to get a monthly Google Ad grant to promote the therapy on the Internet.
Ok, thank you for that. Let’s now jump to the primary focus of our interview. What emerging technologies do you believe will have the most significant impact on your industry in the next five years, and how are you preparing for them?
In the field of cancer treatments, the standard answer to such a question would be “immunotherapies and gene therapies”. Much emphasis would be placed on the personalization of these therapies for each cancer patient in the future.
We strongly disagree.
Immunotherapies are applicable for select cancers and produce benefits in a minority of patients. They also induce untoward side effects and are so expensive that they would be out of reach of most patients. (Personalization of any item always makes it more expensive, since you cannot do mass production to reduce per-item cost.) Cancer gene therapies are even further in the future and have similar shortcomings.
If we may say so, it is the GEIPE Cancer Treatment that would have the most significant impact on the cancer industry, whenever it is ‘allowed to emerge’ or becomes known to the public at large. This universal scientific treatment is effective, non-toxic and very affordable — dream-come-true for cancer patients.
How do you balance the need for rapid innovation with the risk of potential disruptions in your organization?
We are not afraid of disruption. We are the disruptor!
We offer a highly innovative cancer treatment, which would be effective, non-toxic and low-cost. Unfortunately, the potential disruption from this novel therapy — the loss of income for cancer clinics — is so great that there is extreme resistance to this revolutionary cancer therapy.
As author Upton Sinclair of the last century said: “It is difficult to get a man to understand something, when his salary depends on his not understanding it.” The very affordability of this therapy has come in the way of its adaptability by hospitals. It would be too disruptive. The status quo can change only if the general public becomes aware of the existence of this therapy.
Can you share an example of a strategy you’ve implemented to future-proof your business against upcoming technological changes?
We are obviously on the other side. We wish to be the source of “upcoming technological changes” in the field of cancer.
The insight and innovation brought about by our novel cancer therapy would make the most dreaded and most expensive medical treatments into a gentle and very affordable therapy, not to mention more effective.
If and when this treatment is established, there will be a substantial drop in income of cancer institutions. Cancer diagnosis will still be needed but chemotherapy and radiation may become obsolete.
However, the economic upheaval of cancer institutions may last for only one or two years. Oncologists will find new jobs. No country has a surplus of doctors. Also, note that most of the cancers are of internal tissues which cannot be treated by a portable device at home. For them, there will always be a need for hospitals and surgeons.
What skills or mindsets do you believe are essential for leaders to thrive in an era of rapid technological advancement?
- Be keenly aware of the latest advances in the primary technologies of your field and in all adjacent and relevant technologies
- Assemble a competent team of engineers, scientists and managers
- Be ready to merge with other companies that are bringing innovations or license technologies from them
What are your “Five Things You Need to Prepare For The Disruptive Future”?
1 . Learn about the latest technologies in your field of work.
2 . Diversify your expertise.
3 . Have multiple product lines (or offerings) in unrelated fields, so if one product loses market share due to some unforeseen innovative product, you can rely on your other offerings.
4 . Have enough funds so you have means to pivot in a different direction if your field is disrupted.
5 . Be prepared to start over in a related field. (Blackberry phone makers could not survive long when iPhone and Android smartphones came on market, but they are still involved in the development of connected devices and embedded operating systems that are used by millions of vehicles.)
How do you foster a culture within your team that is both adaptable and resilient in the face of fast-paced innovation?
A healthy — but not excessive — amount of paranoia is good.
Team members must be incessantly curious about new technologies in the field and be willing to learn to keep their skill-set up to date.
How do you ensure that ethical considerations and social impact remain a priority as you navigate rapid advancements in technology?
Providing relief and healing to millions of cancer sufferers worldwide, no doubt, will have a major positive social impact. Thus the well-being of the society is not just a priority but the core feature of what our company offers.
The top cancer institutes in both the USA and India showed interest but then balked at exploring and offering this cancer treatment, almost certainly due to its negative financial impact on them. Cancer patients will be shocked to know that the treatment that has the most potential to benefit them, without any toxicity, is not available simply because it will reduce the profits of hospitals.
All ethical arguments are in the favor of this therapy which has been languishing for 30 years.
You are a person of great influence. If you could start a movement that would bring the most amount of good to the most amount of people, what would that be? You never know what your idea can trigger. 🙂
Such a movement was already started by me in 1994, but it has not seen light of the day because of the vested interests of cancer care providers. The GEIPE treatment, once recognized, would transform the gloomy landscape of cancer where too much money is being spent to achieve so little. Cancer patients the world over, rich or poor, would stop dreading the c-word. It would be a ‘dream come true’ for them.
It is noteworthy that cancer researchers who would never do clinical trials of a treatment that cannot be patented often ask us to prove the efficacy of this cancer treatment, by showing results of such trials. This is like Catch-22.
How can our readers further follow your work online?
Please visit the website of GEIPE Cancer Treatment and read about our struggle, view information about treated patients, and other updates. Visitors can also read the 3 scientific articles about this treatment.
Thank you for the time you spent sharing these fantastic insights. We wish you only continued success in your great work!
About the Interviewer: Cynthia Corsetti is an esteemed executive coach with over two decades in corporate leadership and 11 years in executive coaching. Author of the upcoming book, “Dark Drivers,” she guides high-performing professionals and Fortune 500 firms to recognize and manage underlying influences affecting their leadership. Beyond individual coaching, Cynthia offers a 6-month executive transition program and partners with organizations to nurture the next wave of leadership excellence.
The Future is Faster Than You Think: Jay Kulsh Of GEIPE Cancer Treatment Inc On How Leaders Are… was originally published in Authority Magazine on Medium, where people are continuing the conversation by highlighting and responding to this story.